Chemistry:LEK-8822

From HandWiki

LEK-8822, also known as 9,10-dihydro-LEK-8842 or as 9,10-dihydro-N-methyl-N-(2-propynyl)lysergamide, is a monoamine receptor modulator of the lysergamide family related to 9,10-dihydro-LSD.[1] It is the analogue of LEK-8842 in which the double bond between the 9 and 10 positions of the ergoline ring system has been dihydrogenated.[1] The drug is a partial agonist of α-adrenergic receptors, with considerably reduced potency and efficacy compared to LEK-8842.[1] Due to this action, LEK-8822 can produce vasoconstriction.[1] In addition to its α-adrenergic receptor activity, LEK-8822 shows preserved affinity for but elimination of agonist activity at serotonin 5-HT2 receptors compared to LEK-8842.[1] LEK-8822 was first described in the scientific literature by 1992.[1] It was developed by the Slovenian pharmaceutical company LEK Pharmaceuticals.[1]

See also

  • Substituted lysergamide
  • LEK-8842 (9,10-didehydro-LEK-8822)
  • LEK-8841 (2-bromo-LEK-8842)
  • LEK-8829 (desoxy-LEK-8842)
  • 9,10-Dihydro-LSD

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 "Structure-activity study of some newly synthesized ergoline derivatives on 5-HT2 receptors and alpha-adrenoceptors in rabbit isolated aorta". Pharmacology 45 (4): 195–208. 1992. doi:10.1159/000138998. PMID 1332086. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:LEK-8822&oldid=4433272"